Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 13 , ISSUE 2 ( July-December, 2023 ) > List of Articles

Original Article

Role of Biobran (Arabinoxylan Rice Bran) on Patients with Advanced Stage Hepatocellular Carcinoma

Md Ashrafujjaman, Mamun Al Mahtab, Sheikh Mohammad Noor-E-Alam, Md Abdur Rahim, Dulal Chandra Das, Faysal Ahmed, Ayub Al Mamun, Tasnim Mahmud, Tarim Mahmood

Keywords : Biobran, Carcinoma of liver, Food supplement, Terminal stage

Citation Information : Ashrafujjaman M, Al Mahtab M, Noor-E-Alam SM, Rahim MA, Das DC, Ahmed F, Al Mamun A, Mahmud T, Mahmood T. Role of Biobran (Arabinoxylan Rice Bran) on Patients with Advanced Stage Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2023; 13 (2):84-88.

DOI: 10.5005/jp-journals-10018-1407

License: CC BY-NC 4.0

Published Online: 26-12-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Background and objectives: Carcinoma of liver – renowned, has taken third position in world ranking, comparing to other causes for cancer-related death, however, curative treatment of hepatocellular carcinoma (HCC) is largely absent and even proper management of HCC patients is extremely difficult. The situation becomes more complex when HCC patients are attended by physicians in their terminal state. Arabinoxylan rice bran (biobran) is an inherent product and hemicellulose which is denatured, as well as gained by hemicellulose including a number of hydrolyzing enzymes of carbohydrate from Shiitake mushrooms. It enhances activities of different immune cells and may exert some effects in cancer patients. Materials and methods: In this observation study, the implication of biobran was assessed in a small group of 52 HCC patients. One halves of the patient received biobran and the other halves received best supportive care (BSC). Results: Baseline parameters in two groups were mostly comparable. During observation after 30, 60, and 90 days, a total of six, one, and one patient were alive in biobran group, respectively. The survival of cancer patients of the BSC group was comparable at these time points (6, 1, and 0, respectively) with no statistical significance. After 30 days of treatment, those who were survived in biobran group, the mean CP score was 11.00 ± 1.55 and 10.50 ± 0.84 at pretreatment and posttreatment, respectively, (p = 0.20). Conclusion: Biobran may be of some benefit for terminal HCC, however, more studies are warranted to optimize dose and duration of therapy.

  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):359–386. DOI: 10.1002/ijc.29210.
  2. Forman D, Bray F, Brewster DH, et al. Cancer Incidence in Five Continents Vol. X. IARC Scientific Publications No. 164. International Agency for Research on Cancer Lyon, France, 2014. p. 70–75.
  3. Jabeen S, Islam MJ, Talukder MH, et al. Pathoepidemiology of cervical cancer in national institute of cancer research and hospital of Bangladesh. J Dhaka Med Coll 2015;23(2):203–210. DOI: 10.3329/jdmc.v23i2.25392.
  4. Mahtab MA, Karim F, Foster G, et al. Prevalence and risk factors of asymptomatic hepatitis C virus infection in Bangladesh. J Clin Exp Hepatol 2011;1(1):13–16. DOI: 10.1016/S0973-6883(11)60111-4.
  5. Hussain SA, Sullivan R. Cancer control in Bangladesh. Jpn J Clin Oncol 2013;43(12):1159–1169. DOI: 10.1093/jjco/hyt140.
  6. Ghoneum M. Apoptosis and arabinoxylan rice bran, in wheat and rice in disease prevention and health. In: Watson, RR, Preedy VR, Ziba.di S (Eds). Science & Technology Book, Elsevier, 2014. pp. 399–404.
  7. Henderson AJ, Ollila CA, Kumar A, et al. Chemopreventive properties of dietary rice bran: Current status and future prospects. Adv Nutr 2012;3(5):643–653. DOI: 10.3945/an.112.002303.
  8. Kato H, Yoshida H, Taniguch H, et al. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. World J Gastroenterol 2015;21(46):13101–13112. DOI: 10.3748/wjg.v21.i46.13101.
  9. Takahara K, Sano K. The life prolongation and QOL improvement effect of rice bran arabinoxylan derivative (MGN-3. Bio-Bran) for progressive cancer. Clin Pharmacol Ther 2004;14:267–271. DOI:
  10. Suto T, Fukuda S, Moriya N, et al. Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33(Suppl):145–148. DOI: 10.1007/BF00686688.
  11. Bang MH, Riep TV, Thinh NT, et al. Arabinoxylan rice bran (MGN-3) enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: A three-year randomized clinical trial. Anticancer Res 2010;30(12):5145–5151. PMID: 21187503.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.